Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.
Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.
Expert oncologist Ian Hagemann, MD, PhD, shares insight into the process of making a differential diagnosis of low-grade serous ovarian cancer in light of adjacent disease and available IHC testing.
As a result of the Affordable Care Act’s Medicaid expansion, positive trends are becoming apparent regarding mortality rates for patients with cancer living in the states that have adopted Medicaid expansion.
Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.
Amy W. Zhou, MD, discusses combination therapies with ruxolitinib that may contribute to the treatment paradigm for patients with myelofibrosis, highlighting the importance of continued research with phase 3 confirmatory trials for patients with this disease.
Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.
Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis.
Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.
Matthew Powell, MD, presents data from the blinded independent central review of the RUBY trial, which studied dostarlimab in patients with primary advanced or recurrent endometrial cancer.